CD22-Directed CAR-T Therapy Demonstrates Durable Remissions for Patients With Large B-Cell Lymphomas Relapsing After CD19-Directed CAR-T Therapy
At 3 years of follow-up, CD22-directed CAR T-cell therapy continued to show durable remissions for patients with large B-cell lymphomas which had previously relapsed after CD19-directed CAR T-cell therapy.
Anne Marijn Kramer, MD, PhD, Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA presented these results at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, California.
“CAR22 provides durable remissions and long-term survival in CAR19-progressing LBCL patients,” Kramer and colleagues explained. “Late progression or lymphoma-specific death was uncommon, suggesting a curative potential for these patients.”
Source:
Kramer AM, Baird JH, Srinagesh H, et al. CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up. Presented at the 66th ASH Annual Meeting & Exposition; December 7-10, 2024; San Diego, California. Abstract 69.
